Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases.
Ticker:
PGEN
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
1998
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
PRGN 2012: OTS AdenoVerse Immunotherapy in Recurrent Respiratory Papillomatosis (RRP) (Phase II)
PRGN 2009: OTS AdenoVerse Immunotherapy in HPV+ Solid Tumors (Phase II)
AG019: ActoBiotics in Type 1 Diabetes (Phase II)
PRGN 3005: UltraCAR-T in Ovarian Cancer (Phase I)
PRGN 3006: UltraCAR-T in AML, MDS (Phase I)
PRGN 3007: UltraCAR-T in Hematological and Solid Tumors (Phase I)
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
